<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742518</url>
  </required_header>
  <id_info>
    <org_study_id>SM04554-AGA-05</org_study_id>
    <nct_id>NCT03742518</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% &amp; 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey,&#xD;
      will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied&#xD;
      daily to the scalp of male androgenetic alopecia (AGA) subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute non-vellus hair count in target area</measure>
    <time_frame>Week 48</time_frame>
    <description>Absolute non-vellus hair count in target area by phototrichogram (PTG) analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute non-vellus hair count in target area</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Absolute non-vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute vellus hair count in target area</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
    <description>Absolute vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute total hair count in target area</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
    <description>Absolute total hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-vellus hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in non-vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vellus hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in total hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average non-vellus hair shaft thickness in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in average non-vellus hair shaft thickness in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average non-vellus hair density in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in average non-vellus hair density (cumulative non-vellus hair shaft thickness) in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of hair growth</measure>
    <time_frame>Weeks 6, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Subjects will complete a questionnaire for hair growth while referencing the global scalp photograph taken at the visit as compared to their baseline global scalp photograph. The scale for the questionnaire ranges from -3 to +3 (-3 indicates the worst outcome and +3 indicates the best outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject assessment of hair satisfaction</measure>
    <time_frame>Baseline, and Weeks 6, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Subjects will complete a questionnaire for hair satisfaction while referencing the global scalp photograph taken at the visit as compared to their baseline global scalp photograph. The scale for the questionnaire ranges from -3 to +3 (-3 indicates the worst outcome and +3 indicates the best outcome).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">675</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Topical SM04554 0.15% solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.15% solution, once daily for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical SM04554 0.25% solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.25% solution, once daily for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical vehicle solution, once daily for up to 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical SM04554 solution</intervention_name>
    <description>Study medication application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Topical SM04554 0.15% solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical SM04554 solution</intervention_name>
    <description>Study medication application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Topical SM04554 0.25% solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical vehicle solution</intervention_name>
    <description>Vehicle solution application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being a Turkish citizen&#xD;
&#xD;
          -  Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 3V or 4&#xD;
&#xD;
          -  Willing to inform females, with whom they may interact, that they are using a topical&#xD;
             investigational product and direct contact should be avoided as potential harm to a&#xD;
             fetus is unknown&#xD;
&#xD;
          -  Willing and able to attend all study visits&#xD;
&#xD;
          -  Willing to maintain the same hair style and length as at the study start for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers)&#xD;
             for the duration of the study; daily styling products (e.g., hair gel, mousse, styling&#xD;
             spray) will be allowed on non-study visit days&#xD;
&#xD;
          -  Willing to use mild non-medicated shampoo and conditioner for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Able to read and understand Turkish&#xD;
&#xD;
          -  Ability to comprehend and willing to sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Males who are sexually active, and have a partner who is capable of becoming pregnant,&#xD;
             if neither has had surgery to become sterilized, and/or who are not willing to use&#xD;
             condom or whose partner is not using a highly effective method of birth control that&#xD;
             includes double barrier, intrauterine device, or hormonal contraceptive combined with&#xD;
             single barrier, or abstinence during the study treatment period until 90 days post&#xD;
             last dose of study medication&#xD;
&#xD;
          -  Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia&#xD;
&#xD;
          -  Scalp hair loss on the treatment area, due to disease, injury, or medical therapy&#xD;
&#xD;
          -  History of surgical correction (e.g., hair transplantation, scalp reduction) of hair&#xD;
             loss on the scalp&#xD;
&#xD;
          -  Previous exposure to SM04554&#xD;
&#xD;
          -  Use of any products (e.g., finasteride, minoxidil, platelet rich plasma, biotin) or&#xD;
             devices (e.g., laser light therapy) purported to promote scalp hair growth within 24&#xD;
             weeks prior to the start of the study&#xD;
&#xD;
          -  Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone&#xD;
             acetate, cimetidine) within 12 weeks prior to the start of the study&#xD;
&#xD;
          -  Use of medications that potentially cause drug-induced hair loss (e.g.,&#xD;
             depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone,&#xD;
             testosterone, divalproex sodium) within 12 weeks prior to the start of the study&#xD;
&#xD;
          -  Current use of an occlusive wig, hair extensions, or hair weaves&#xD;
&#xD;
          -  History of hypersensitivity or allergies to any ingredient of the study medication&#xD;
&#xD;
          -  Participation in any other investigational drug or medical device trial, which&#xD;
             includes or included administration of an investigational study medication or medical&#xD;
             device, within 30 days or 5 half-lives of the investigational agent, whichever is&#xD;
             longer, prior to the start of the study&#xD;
&#xD;
          -  Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30&#xD;
             days prior to the start of the study&#xD;
&#xD;
          -  Use of medicated shampoo or conditioner (medicated shampoo and conditioner refers to&#xD;
             any prescription shampoo or conditioner as well as any over-the-counter medicated&#xD;
             shampoo or conditioner, such as those for treatment of dandruff or promoting hair&#xD;
             growth) within 30 days prior to the start of the study&#xD;
&#xD;
          -  Subjects who are immediate family members (spouse, parent, child, or sibling;&#xD;
             biological or legally adopted) of personnel directly affiliated with the study at the&#xD;
             investigative site, or are directly affiliated with the study at the investigative&#xD;
             site&#xD;
&#xD;
          -  Subjects employed by Samumed, LLC or Samumed Turkey, or any of its affiliates or&#xD;
             development partners (i.e., an employee, temporary contract worker, or designee)&#xD;
             responsible for the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06680</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ä°zmir</city>
        <zip>35180</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male pattern baldness</keyword>
  <keyword>SM04554</keyword>
  <keyword>AGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

